Proteomics-driven cancer biomarker discovery: looking to the future.

@article{citeulike:2463140, abstract = {Availability of a suite of biomarkers for early detection, stratification into distinct subtypes, and monitoring progression or response to therapy promises significant improvements in clinical outcomes for cancer patients. However, despite the recent progress in proteomics technologies based on mass spectrometry (MS), discovery of novel clinical assessment tools has been slow. This is, partly due to the inherent difficulties in working with blood as the biospecimen for candidate discovery. A better understanding of the limitations of blood for comparative protein profiling and a better appreciation of the advantages of cancer tissue or cancer cell secretomes have the potential to greatly enhance the progress.}, address = {Joint Proteomics Laboratory, Ludwig Institute for Cancer Research and the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3055, Australia.}, author = {Simpson, Richard J J. and Bernhard, Oliver K K. and Greening, David W W. and Moritz, Robert L L. }, citeulike-article-id = {2463140}, doi = {10.1016/j.cbpa.2008.02.010}, issn = {1367-5931}, journal = {Curr Opin Chem Biol}, month = {February}, posted-at = {2008-03-04 04:34:32}, priority = {2}, title = {Proteomics-driven cancer biomarker discovery: looking to the future.}, url = {http://dx.doi.org/10.1016/j.cbpa.2008.02.010}, year = {2008} }

TY - JOUR ID - citeulike:2463140 L3 - citeulike-article-id:2463140 TI - Proteomics-driven cancer biomarker discovery: looking to the future. JF - Curr Opin Chem Biol AD - Joint Proteomics Laboratory, Ludwig Institute for Cancer Research and the Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3055, Australia. SN - 1367-5931 N2 - Availability of a suite of biomarkers for early detection, stratification into distinct subtypes, and monitoring progression or response to therapy promises significant improvements in clinical outcomes for cancer patients. However, despite the recent progress in proteomics technologies based on mass spectrometry (MS), discovery of novel clinical assessment tools has been slow. This is, partly due to the inherent difficulties in working with blood as the biospecimen for candidate discovery. A better understanding of the limitations of blood for comparative protein profiling and a better appreciation of the advantages of cancer tissue or cancer cell secretomes have the potential to greatly enhance the progress. AU - Simpson, Richard J AU - Bernhard, Oliver K AU - Greening, David W AU - Moritz, Robert L PY - 2008/02/21/ UR - http://dx.doi.org/10.1016/j.cbpa.2008.02.010 ER -